The 19 analysts offering 12-month price forecasts for Biomarin Pharmaceutical Inc have a median target of 105.00, with a high estimate of 165.00 and a low estimate of 81.00. The median estimate represents a +38.32% increase from the last price of 75.91.
The current consensus among 22 polled investment analysts is to Buy stock in Biomarin Pharmaceutical Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.25
Reporting Date Oct 27
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.